BioSpace

00:19:16

From Sound Bites to Signals: Editors Parse Executive...

BioSpace ·

2026/01/22

In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.Hosts⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpace⁠Guests⁠Annalee Armstrong, Senior Editor, BioSpace⁠Dan Samorodnitsky, News Editor, BioSpaceDisclaimer: The views expressed in this discussion by guests are their own and do not

en

00:21:18

JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s...

BioSpace ·

2026/01/21

The 2026 J.P. Morgan Healthcare Conference concludedlast week without a big M&A deal. But the meeting was anything but boring, with President Donald Trump’sMost Favored Nation drug pricing scheme and the perpetual battle for supremacyin the obesity space between Eli Lilly and Novo Nordisk prime topics of conversation. Meanwhile, other companies like Biohaven refuse tocede the entire weight loss market, stating their intention to carve out apiece of the massive pie. On the competitive front,

en

00:07:49

Bonus: Q4 2025 Job Market Update

BioSpace ·

2026/01/19

In this episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss Q4 2025 job market performance, sharing the latest BioSpace data. They touch on positive signs they saw last quarter and what this year might have in store for those seeking employment. Want to receive our latest quarterly job market reports as soon as they’re published? ⁠⁠⁠Subscribe⁠⁠⁠ to Career Insider for our job market updates, job trends, career advice and more.

en

00:20:02

Deals Roll at JPM26, Policy Front and Center, IPOs...

BioSpace ·

2026/01/14

AbbVie bet nearly $5 billion for the ex-China rights to RemeGen’s PD-1/VEGF bispecific and Novartis struck a $1.5 billion Alzheimer’s-focused deal with China-based SciNeuro Pharmaceuticals as the 2026 J.P. Morgan Healthcare Conference got underway on Monday. These and other recent tie-ups speak to the therapeutic trends predicted to be hot this year by experts who spoke with BioSpace, who particularly noted that cancer and neuroscience would remain top of the list. Meanwhile, attendees are still

en

00:24:21

From Nuclear Winter to Renewal: Biotech Investing for...

BioSpace ·

2026/01/08

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsMaha Katabi, General Partner, Sofinnova InvestmentsAndrew Lam, Managing Director, Head of Biotech Private

en

00:23:19

Novo Launches Oral Obesity Pill, Lilly Targets Lofty...

BioSpace ·

2026/01/07

Obesity titans Novo Nordisk and Eli Lilly characteristically kicked off 2026 in the headlines. After capping 2025 with the first-ever FDA approval of an oral GLP-1 for obesity, Novo launched its Wegovy pill on Monday, starting at $149 per month out of pocket for the lower doses. Meanwhile, all eyes are on Lilly, which expects a greenlight for orforglipron as early as March. The oral weight loss play is set to be a key aspect of a pivotal year for Lilly, which hopes to more than double its annual

en

00:28:37

Inside the 2026 Biotech Landscape: Innovation,...

BioSpace ·

2025/12/18

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about how renewed confidence is driving biotech entering 2026. As we look towards conversations that will shape this year's J.P. Morgan Healthcare Conference, the biotech industry is fueled by improving market sentiments, visible at recent meetings like Jeffries in London, and reinforced by a wave of partnerships, strategic acquisitions and Chinese

en

00:20:04

Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s...

BioSpace ·

2025/12/17

Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results from the Phase III TRIUMPH-4 trial exceeded analyst expectations, leading BMO Capital markets to cleverly dub it “a true TRIUMPH.” Also in the weight loss arena, Zealand Pharma inked a deal with China’s OTR Therapeutics worth up to $2.5 billion to collaborate on next-gen drugs for obesity and other metabolic diseases, and Rhythm Pharmaceuticals awaits a

en

00:40:21

Beyond the Gluten-Free Diet: A New Era in Celiac...

BioSpace ·

2025/12/11

In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology, The Mayo Clinic; Marilyn Gellar, CEO, The Celiac Disease Foundation; and Dr. Paul Lizzul, chief medical officer, AnaptysBio, about the unmet need for effective treatments for celiac disease, the limitations of the gluten-free diet and the development of ANB033, a first-in-class CD122

en

00:21:30

Weight Loss Waves, Pazdur’s Exit and FDA Instability,...

BioSpace ·

2025/12/10

Pfizer followed up its winning $10 billion bid forobesity startup Metsera by adding another molecule to its obesity cabinet, thisone from Chinese firm YaoPharma in a deal worth up to $1.9 billion licensing deal announced Tuesday. Meanwhile, Wave Life Sciences and Structure Therapeutics may have changed the weight loss landscape with early and mid-stagedata from their candidates that analysts called “very disruptive” and “highlycompetitive,” respectively. At the FDA, the confusion and instability

en

00:25:01

New Approach Methodologies: Redefining Animal Testing...

BioSpace ·

2025/12/04

Momentum is building behind New Approach Methodologies (NAMs) that offer stronger human relevance than traditional animal testing. The FDA issued on December 2 a draft guidance outlining specific product types for which the agency believes six-month non-human primate toxicity testing can be eliminated or reduced. The guidance followed a proposed agency template for NAMs in April. There is also an initiative called the Validation and Qualification Network, with dozens of partners from regulators,

en

00:22:39

Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs,...

BioSpace ·

2025/12/03

Vinay Prasad’s memo, leaked over the weekend, has sent vaccine makers’ stocks slipping and experts clamoring for more evidence to support the CBER director’s claim that COVID vaccines have led to the deaths of at least 10 children. It’s the latest insult to the vaccine sector from the healthcare administration this year, with other challenges coming on the CDC side, where the recently revamped advisory committee is heading into its next meeting with a brand new chair. Elsewhere at the FDA, newly

en

00:21:19

Billions More in M&A, Another Bidding War and More...

BioSpace ·

2025/11/19

Acquisitions have ticked up this month as all eyes were on Pfizer and Novo’s fight over Metsera. The past week saw that deal finalized with Pfizer as the winner plus a handful of other M&A stories, including Merck’s $9.2 billion buyout of Cidara Therapeutics and Johnson & Johnson’s $3 billion bet on Halda Therapeutics. Additionally, a separate bidding war has broken out between Lundbeck and Alkermes for sleep biotech Avadel Pharmaceuticals. Outside of M&A, the FDA dominated headlines

en

00:21:13

How Biotech Funding is Changing Executive Search and...

BioSpace ·

2025/11/13

A lean funding environment has changed how biotechs approach workforce organization and executive hiring. Searches are becoming more targeted and intentional, and accountability–both for employers and candidates–is high. In this episode of Denatured, Leslie Loveless of Slone Partners describes how biotechs should approach building their executive teams, working with boards and investors to make decisions that will enable growth. She also discusses how the search and hiring processes has changed for

en

00:27:51

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing...

BioSpace ·

2025/11/12

One of biopharma’s most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will

en

00:10:43

Thoughtful Tech: How Removing Technological Burdens...

BioSpace ·

2025/11/06

This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our guests continue their discussion on how autoinjectors and smart technologies can be integrated into clinical trials in a way that isn’t problematic or burdensome for patients, particularly for patients that may not be tech savvy. They discuss that by focusing on patient experience, clinical trials can increase engagement and compliance.This episode is

en

00:26:26

Pfizer and Novo Battle Over Metsera, Tidmarsh Fights...

BioSpace ·

2025/11/05

Many of the top stories of 2025 are currently being written. We’re on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out over the right to acquire glittery obesity startup Metsera. In the latest development, Pfizer raised its original bid of around $7.27 billion to about $8.1 billion on Monday—only to be usurped again by the indefatigable Novo, which upped its own bid to a cool $10 billion. Meanwhile, the unprecedented drama in the uppermost ranks of the

en

00:14:15

Innovation, Resilience, and the Future of Global...

BioSpace ·

2025/10/30

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how China, historically focused on manufacturing, is increasingly becoming an innovation leader, particularly in pharmaceuticals. Ultimately, balanced strategies involve domestic capacity investments coupled with global collaboration.This episode is presented in partnership with Element Materials Technology.HostsJennifer Smith-Parker, Director of Insights, BioSpaceLori Ellis, Head of Insights, BioSpaceGuestsDr

en

00:26:36

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped...

BioSpace ·

2025/10/29

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That’s the second biggest buy of the year after Johnson & Johnson’s January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis’

en

00:08:59

How Supply Chain Turbulence is Reshaping Biotech...

BioSpace ·

2025/10/23

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to international harmonization standards as a stable template. U.S. tariffs are redefining competitiveness in manufacturing nations like India, China, and other parts of Asia, with China emerging as a global innovator.This episode is presented in partnership with Element Materials Technology.HostsJennifer Smith-Parker, Director of Insights, BioSpaceLori Ellis,

en

All Episodes

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media

Physics World Weekly Podcast

Physics World

La Science, CQFD

France Culture